CN113557022A - 用罗达司他乙酯治疗肺动脉高压的给药方案和方法 - Google Patents

用罗达司他乙酯治疗肺动脉高压的给药方案和方法 Download PDF

Info

Publication number
CN113557022A
CN113557022A CN202080016400.5A CN202080016400A CN113557022A CN 113557022 A CN113557022 A CN 113557022A CN 202080016400 A CN202080016400 A CN 202080016400A CN 113557022 A CN113557022 A CN 113557022A
Authority
CN
China
Prior art keywords
kar5585
dose
auc
day
kar5417
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080016400.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·帕拉西奥斯
E·J·高克尔
S·A·玲
M·阿隆索-加力西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altawante Science
Original Assignee
Altawante Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altawante Science filed Critical Altawante Science
Publication of CN113557022A publication Critical patent/CN113557022A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080016400.5A 2019-01-30 2020-01-30 用罗达司他乙酯治疗肺动脉高压的给药方案和方法 Pending CN113557022A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962798827P 2019-01-30 2019-01-30
US62/798,827 2019-01-30
PCT/IB2020/000074 WO2020157577A1 (en) 2019-01-30 2020-01-30 A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl

Publications (1)

Publication Number Publication Date
CN113557022A true CN113557022A (zh) 2021-10-26

Family

ID=70285725

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080016400.5A Pending CN113557022A (zh) 2019-01-30 2020-01-30 用罗达司他乙酯治疗肺动脉高压的给药方案和方法

Country Status (9)

Country Link
US (2) US11607413B2 (https=)
EP (1) EP3917531A1 (https=)
JP (1) JP2022518944A (https=)
KR (1) KR20210133953A (https=)
CN (1) CN113557022A (https=)
AU (1) AU2020213746A1 (https=)
CA (1) CA3128327A1 (https=)
MX (1) MX2021009055A (https=)
WO (1) WO2020157577A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113227093A (zh) * 2018-11-14 2021-08-06 阿尔塔万特科学公司 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022507533A (ja) * 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20200188399A1 (en) * 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
US11607413B2 (en) 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
WO2023062595A1 (en) 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764902A (zh) * 2013-09-06 2016-07-13 卡罗斯制药公司 作为色氨酸羟化酶抑制剂的螺环化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815534A (zh) 2007-07-11 2010-08-25 莱西肯医药有限公司 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物
KR20210102887A (ko) 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
JP2022507533A (ja) 2018-11-16 2022-01-18 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20200188399A1 (en) 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
WO2020128608A1 (en) 2018-12-17 2020-06-25 Altavant Sciences Gmbh Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension
US11607413B2 (en) 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
US11576915B2 (en) * 2019-03-15 2023-02-14 Altavant Sciences Gmbh Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764902A (zh) * 2013-09-06 2016-07-13 卡罗斯制药公司 作为色氨酸羟化酶抑制剂的螺环化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERT J. AIELLO ET AL: "Tryptophan hydroxylase 1(TPH1) inhibition impacts pulmonary vascular remodeling in two ratmodels of pulmonary hypertension", 《J PHARMACOL EXP THER》, vol. 360, no. 2, pages 267 - 279, XP055670218, DOI: 10.1124/jpet.116.237933 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113227093A (zh) * 2018-11-14 2021-08-06 阿尔塔万特科学公司 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法

Also Published As

Publication number Publication date
US11607413B2 (en) 2023-03-21
JP2022518944A (ja) 2022-03-17
CA3128327A1 (en) 2020-08-06
US20200237759A1 (en) 2020-07-30
AU2020213746A1 (en) 2021-08-19
WO2020157577A8 (en) 2020-10-15
MX2021009055A (es) 2021-10-22
WO2020157577A1 (en) 2020-08-06
EP3917531A1 (en) 2021-12-08
US20240041877A1 (en) 2024-02-08
KR20210133953A (ko) 2021-11-08

Similar Documents

Publication Publication Date Title
CN113557022A (zh) 用罗达司他乙酯治疗肺动脉高压的给药方案和方法
US10561618B2 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
JP2018535244A (ja) 関節疾患及び皮膚疾患の治療のためのラパマイシンとメトホルミンの併用
JP5978216B2 (ja) テオフィリンとフェブキソスタットの併用療法のための方法
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
JP6145946B2 (ja) 併用ａｌｓ療法
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
US20170326141A1 (en) Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
JP2022549137A (ja) イブジラスト経口製剤およびその使用方法
TW201204360A (en) Treatment of multiple sclerosis with MASITINIB
US20240197756A1 (en) Methods of treatment with neuroactive steroids
HK40062167A (en) A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
US20220339131A1 (en) Treatment of cns disorders with sleep disturbances
TW201934123A (zh) 預防或治療癌症之包含pi3激酶抑制劑與細胞毒性抗癌物的醫藥組成物
JP2020525548A (ja) 炎症反応を伴う疼痛状態における鎮痛のための末梢限局的二重作用性κおよびδオピオイドアゴニスト
HK1207285B (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062167

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211026